A Single-Centre, Single-Administration, Dose-Escalation Study and A Single-Centre, Randomized, Open-Label, Two-cycle Crossover Food Effect Study of SKLB1028 in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- SKLB1028
- Conditions
- Healthy Subjects
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 26
- Locations
- 1
- Primary Endpoint
- Maximum plasma concentration (Cmax) of SKLB1028 in Part 2
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study was to explore the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of SKLB1028 in healthy subjects. This study has also explored the effect of food on the PK of SKLB1028.
Detailed Description
The study was divided into 2 parts. Part 1(Dose Escalation) included 2 cohorts (Cohort 1 and Cohort 2) and subjects received a single oral dose of SKLB1028 50 or 100 mg on Day 1. In Part 2 (Food Effect) included 2 cohorts (Cohort A and Cohort B), subjects received a single oral dose of SKLB1028 150 mg in a fasting and a fed state, with a 10-day washout period between the 2 doses.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy subjects:
- •Male or female subjects aged 18 to 45 (including 18 and 45 years old), and the proportion of single sex should not be less than 1/3;
- •Male weight ≥50.0 kg, female weight ≥45.0 kg; body mass index (BMI) 18-24 kg/m\^2 (inclusive);
- •Normal or abnormal results without clinically significance on all tests including medical history, physical examination, vital signs, clinical laboratory tests (routine blood test, blood biochemistry, routine urine test, coagulation function), etc;
- •Subjects are willing to use effective non-hormonal contraceptives such as condom and intrauterine device without medication, and not allowed to donate sperm from screening to the 6 months after the last dose administration unless permanent contraception has been taken, such as bilateral tubal ligation and vasectomy;
- •Voluntarily sign the informed consent form, and be willing to comply with the protocol.
Exclusion Criteria
- •Previous or current clear psychiatric/neurological systems diseases; previous or current severe diseases, such as cardiovascular, liver and kidney, endocrine, respiratory, hematological, digestive and immune systems diseases; previous or current malignant tumors;
- •Allergic constitution, including a history of allergy to one or more medications, or other known severe allergic reactions;
- •Inability to swallow oral medications; previous or current diseases that may affect the absorption, distribution, metabolism, or excretion of the drug, or affect the evaluation of efficacy and safety of the drug, such as active bowel disease, partial or complete bowel obstruction and chronic diarrhea;
- •Previous or current diseases such as gastrointestinal ulcer and related bleeding;
- •Abnormalities of clinical significance in electrocardiogram (such as QTcF≥450 ms in males or ≥470 ms in females) or history of prolonged QTcF interval;
- •Any abnormalities of clinical significance in vital signs;
- •Any positive test result of hepatitis B surface antigen or hepatitis C virus antibody, or anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific antibody;
- •Use of any prescription drugs, over-the-counter drugs, biologicals, proprietary Chinese medicine, herbal medicine, dietary supplements, health products, long-acting oral contraceptives or implantable long-acting contraceptives within 2 weeks prior to screening;
- •Use of any strong inhibitors or inducers of CYP3A4, CYP2C8 or P-gp within 2 weeks prior to screening;
- •Average daily intake of alcohol more than 14 units (14 units ≈285 mL of beer, or 25 mL of liquor, or 150 mL of wine) within 4 weeks prior to signature of informed consent, or a positive ethanol breath test at screening;
Arms & Interventions
Dose Escalation Cohort 1: single oral dose of SKLB1028
Eligible subjects received a single dose of SKLB1028 50 mg on Day 1.
Intervention: SKLB1028
Dose Escalation Cohort 2: single oral dose of SKLB1028
Eligible subjects received a single dose of SKLB1028 100 mg on Day 1.
Intervention: SKLB1028
Food Effect Cohort A: SKLB1028, fasted dosing followed by fed dosing
Eligible subjects received a single dose of SKLB1028 150 mg on Day 1 in a fasting state, and a single dose of SKLB1028 150 mg on Day 11 in a fed state, with a 10-day washout period between the 2 doses.
Intervention: SKLB1028
Food Effect Cohort B: SKLB1028, fed dosing followed by fasted dosing
Eligible subjects received a single dose of SKLB1028 150 mg on Day 4 in a fed state, and a single dose of SKLB1028 150 mg on Day 14 in a fasting state, with a 10-day washout period between the 2 doses.
Intervention: SKLB1028
Outcomes
Primary Outcomes
Maximum plasma concentration (Cmax) of SKLB1028 in Part 2
Time Frame: Pre-dose and multiple timepoints up to 144 hours post-dose
Area under the concentration-time curve from time 0 to last quantifiable concentration (AUC0-last) of SKLB1028 in Part 2
Time Frame: Pre-dose and multiple timepoints up to 144 hours post-dose
Area under the concentration-time curve from time 0 to infinity (AUCinf) of SKLB1028 in Part 2
Time Frame: Pre-dose and multiple timepoints up to 144 hours post-dose
Time to Cmax (Tmax) of SKLB1028 in Part 2
Time Frame: Pre-dose and multiple timepoints up to 144 hours post-dose
Terminal-elimination half-life (T1/2) of SKLB1028 in Part 2
Time Frame: Pre-dose and multiple timepoints up to 144 hours post-dose
Apparent volume of distribution (Vz/F) of SKLB1028 in Part 2
Time Frame: Pre-dose and multiple timepoints up to 144 hours post-dose
Number of participants with treatment-related adverse events (TEAEs)
Time Frame: Throughout the study period, with an average of 10 days.
TEAEs were assessed by CTCAE v5.0 in Part 1
Apparent clearance (CLz/F) of SKLB1028 in Part 2
Time Frame: Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary Outcomes
- Number of participants with TEAEs(Throughout the study period, with an average of 20 days)
- Maximum plasma concentration ( Cmax) of SKLB1028 in Part 1(Pre-dose and multiple timepoints up to 144 hours post-dose)
- Area under the concentration-time curve from time 0 to last quantifiable concentration (AUC0-last) of SKLB1028 in Part 1(Pre-dose and multiple timepoints up to 144 hours post-dose)
- Apparent volume of distribution (Vz/F) of SKLB1028 in Part 1(Pre-dose and multiple timepoints up to 144 hours post-dose)
- Area under the concentration-time curve from time 0 to infinity (AUCinf) of SKLB1028 in Part 1(Pre-dose and multiple timepoints up to 144 hours post-dose)
- Time to Cmax (Tmax) of SKLB1028 in Part 1(Pre-dose and multiple timepoints up to 144 hours post-dose)
- Terminal-elimination half-life (T1/2) of SKLB1028 in Part 1(Pre-dose and multiple timepoints up to 144 hours post-dose)
- Apparent Clearance (CLz/F) of SKLB1028 in Part 1(Pre-dose and multiple timepoints up to 144 hours post-dose)